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nflammatory Markers and the Metabolic Syndrome
nsights From Therapeutic Interventions
wang Kon Koh, MD, PHD, FACC,* Seung Hwan Han, MD,* Michael J. Quon, MD, PHD†
ncheon, South Korea; and Bethesda, Maryland
Inflammation in the vasculature might be an important pathogenic link between cardiovas-
cular diseases and the metabolic syndrome. Inflammation can be reduced by a variety of
approaches including diet, exercise, cardiovascular drugs, and insulin sensitizers. Importantly,
these different measures improve vascular function and reduce inflammation by distinct
mechanisms. Therefore, combination therapy including lifestyle modifications and multiple
drugs from separate classes might produce additive beneficial outcomes. We review plausible
mechanisms for effects of combination therapy to reduce inflammation, improve endothelial
dysfunction, and decrease insulin resistance in atherosclerosis, coronary heart disease, and
hypertension in the context of insulin-resistant states including diabetes, obesity, and the
metabolic syndrome. (J Am Coll Cardiol 2005;46:1978–85) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.082College of Cardiology Foundation
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sypercholesterolemia (1), hypertension (1), estrogen defi-
iency (2), and insulin resistance (3) contribute to endothe-
ial dysfunction accompanied by inflammation in the vessel
all, increased lipoprotein oxidation, smooth muscle cell
roliferation, extracellular matrix deposition, accumulation
f lipid-rich material, activation of platelets, and thrombus
ormation. These pathogenic features contribute to devel-
pment of atherosclerosis and coronary heart disease (2–5).
erial angiographic studies performed before and after
yocardial infarction indicate that the underlying plaque
esponsible for unstable angina and myocardial infarction
sually produces an arterial narrowing of 50% before the
cute event (6). Thus, mechanisms in addition to luminal
cclusion are likely to be important determinants of plaque
upture, activation of platelets, and thrombus formation that
ulminate in acute coronary events. In this review, we
iscuss the role of inflammatory markers in linking endo-
helial dysfunction in cardiovascular diseases with metabolic
isorders, including diabetes, obesity, and the metabolic
yndrome. Particular emphasis is given to insights derived
rom therapeutic interventions with diet, exercise, cardio-
ascular drugs, insulin sensitizers, and combination thera-
ies that have important anti-inflammatory actions.
NFLAMMATION AND ATHEROSCLEROSIS
hronic inflammation is a pathogenic feature of atheroscle-
osis (Fig. 1) (4). Initiation of vascular inflammation is
ultifactorial. Direct injury to the vessel wall causes endo-
helial and smooth muscle cells of large arteries to become
ranscriptionally active and synthesize pro-inflammatory
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ncheon, Korea; and the †Diabetes Unit, Laboratory of Clinical Investigation,
ational Center for Complementary and Alternative Medicine, National Institutes of
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ccepted June 27, 2005.roteins, including chemokines, cell adhesion molecules
CAMs), and cytokines as well as growth factors and
rothrombogenic substances. Cytokine-activated macro-
hages and smooth muscle cells secrete matrix metallopro-
einases, which, when activated, digest connective tissue
lements within the vessel wall and thin the fibrous cap
verlying vulnerable plaques. This increases the potential for
laque rupture with exposure of thrombogenic plaque con-
ents (7).
Endothelial dysfunction characterized by reduced pro-
uction of nitric oxide (NO) and increased synthesis and
ecretion of endothelin-1 enhances vasoconstrictor tone and
ncreases synthesis and release of pro-inflammatory cyto-
ines. Decreased NO production also promotes platelet
ggregation and release of growth factors in the vessel wall
2–5). Importantly, elevated levels of free fatty acids asso-
iated with insulin resistance, obesity, diabetes, and the
etabolic syndrome cause endothelial dysfunction by acti-
ating innate immune inflammatory pathways upstream of
uclear transcription factor, nuclear factor (NF)-kappaB
3). Thus, inflammation contributes to endothelial dysfunc-
ion while endothelial dysfunction promotes inflammation.
he resultant decrease in NO bioactivity is important in
nitiation and progression of atherosclerosis. Taken to-
ether, these findings help to explain why markers of acute
nflammation reflect increased cardiovascular risk (8,9) and
he transition from stable to unstable angina is associated
ith a systemic inflammatory response (8).
NFLAMMATION BIOMARKERS
ND THERAPEUTIC INTERVENTIONS
ro-inflammatory states enhancing innate immune signal-
ng results in activation of NF-kappaB that regulates tran-
cription of adhesion molecules vascular cell adhesion mol-
cule (VCAM)-1 and intercellular adhesion molecule
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December 6, 2005:1978–85 Inflammatory Markers and Metabolic SyndromeICAM)-1; NF-kappaB also activates transcription of genes
ncoding chemoattractant factors, including monocyte che-
otactic peptide and macrophage stimulatory factor that
ttract monocytes into vessel walls (Fig. 2). Moreover,
F-kappaB promotes synthesis and release of pro-
nflammatory cytokines that enhance attachment of mono-
ytes and macrophages to vessel walls (2).
AMs. Serum concentrations of CAMs are higher in
atients with coronary artery disease than in healthy control
ubjects (10). Moreover, men in the Physician’s Health
tudy with levels of ICAM-1 in the highest quartile are at
reater cardiovascular risk than men in the lowest quartile
11). Age-adjusted soluble ICAM-1 and VCAM-1 levels
ncrease in a stepwise fashion across tertiles for common
arotid intima-media thickness (12). Thus, systemic inflam-
ation might contribute to development of atherosclerosis.
Ito et al. (13) assessed the effect of weight reduction on
oluble ICAM-1 and soluble E-selectin. Their program
onsisted of lectures on diet, exercise sessions, and behav-
oral modification. After three months, soluble ICAM-1
nd soluble E-selectin, as well as body fat mass, decreased in
he intervention group, with no changes in the control
igure 1. Injury to the arterial surface activates endothelial cells and
nitiates synthesis of pro-inflammatory proteins including chemokines, cell
dhesion molecules, and cytokines as well as growth factors and prothrom-
ogenic substances. Monocytes attracted into the vessel wall are trans-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAMs  cell adhesion molecules
CRP  C-reactive protein
ICAM  intercellular adhesion molecule
IL  interleukin
LDL  low-density lipoprotein
MCP  monocyte chemoattractant protein
NF  nuclear factor
NO  nitric oxide
PPAR  peroxisome proliferator-activated receptor
sCD40L  soluble CD40 ligand
TNF  tumor necrosis factor
VCAM  vascular cell adhesion moleculet
ormed into macrophages, which incorporate oxidized low-density lipopro-
ein (LDL), becoming lipid-laden foam cells. Modified from Koh KK (2).ubjects. Soluble ICAM-1 and soluble E-selectin were
ositively correlated with central obesity. In postmenopausal
omen, a high-fiber, low-fat diet and aerobic exercise
ignificantly reduces glucose, insulin, C-reactive protein
CRP), and soluble ICAM-1 with an increase in insulin
ensitivity after two weeks (14).
Simvastatin and candesartan significantly reduce soluble
CAM-1 levels in hypercholesterolemic patients (15,16).
hree-month therapy with the peroxisome proliferators-
ctivated receptor (PPAR)-alpha agonist fenofibrate signif-
cantly decreases CAMs levels in hypertriglyceridemic
atients (17). Interestingly, rosiglitazone treatment for 24
eeks significantly reduces CRP, von Willebrand factor,
nsulin resistance, and mean low-density lipoprotein (LDL)
ensity without changing flow-mediated dilation or
CAM-1 or VCAM-1 levels in men with coronary artery
isease without diabetes mellitus. Rosiglitazone treatment
ignificantly increases LDL and triglyceride levels. Rosigli-
azone reduces markers of inflammation and endothelial
ctivation, but this does not translate into an improvement
n flow-mediated dilation. Increased LDL and triglyceride
evels might be responsible for this finding (18). It is also
mportant to note, however, that several large meta-analyses
f studies examining effects of thiazolidinediones on cardio-
ascular risk factors and dyslipidemias in patients with type
diabetes find that pioglitazone significantly lowers triglyc-
rides along with improving insulin sensitivity and increas-
ng high-density lipoprotein cholesterol with a neutral effect
n LDL cholesterol (19,20). Rosiglitazone, however, in-
reases both high-density lipoprotein and LDL cholesterol
ith a neutral effect on triglycerides (19). Nevertheless,
ead-to-head comparisons between these two different gli-
igure 2. Many stimuli initiate transcription of genes in endothelium that
ncode protein mediators of inflammation and hemostasis. Statins and
brates might modulate this process by inhibiting activation of nuclear
ranscription factor, NF-kappaB. Angiotensin-converting enzyme (ACE)
nhibitors or angiotensin II type I receptor blockers (ARBs) modulate this
rocess by inhibiting binding of angiotensin II to type I receptor, which
ecreases activation of NF-kappaB by oxygen free radicals. Modified from
oh KK (2).azones are necessary to make firm conclusions regarding
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Inflammatory Markers and Metabolic Syndrome December 6, 2005:1978–85he beneficial effects of pioglitazone versus rosiglitazone on
ipid profiles in insulin-resistant states.
onocyte chemoattractant protein (MCP)-1. Patients
ith angina have significantly elevated levels of MCP-1
hen compared with control subjects. Higher levels are seen
n unstable angina when compared with stable angina (21).
n a large population-based study, plasma levels of MCP-1
ere associated with traditional risk factors for atheroscle-
osis, supporting the hypothesis that MCP-1 mediates
therogenic effects (22).
Yang et al. (23) evaluated effects of a high-cholesterol diet
nd parallel exercise training on vascular function in rabbit
ortas. A high-cholesterol diet causes significant lipid depo-
ition and expression of P-selectin, VCAM-1, MCP-1, and
nducible NO synthase. These changes are significantly
educed by exercise training. Troseid et al. (24) recently
howed beneficial effects of combining exercise and prava-
tatin therapy with respect to levels of MCP-1 and IL-8 in
ubjects with the metabolic syndrome. After 12 weeks of
xercise, plasma MCP-1 levels were reduced (p  0.098).
f interest, combined therapy with exercise and pravastatin
herapy significantly reduces MCP-1 levels even further
p  0.01) when compared with baseline.
Angiotensin II activates NF-kappaB through angiotensin
I type 1 and type 2 receptors and induces MCP-1 expres-
ion in cell culture (25). In hypertensive patients, candesar-
an therapy significantly reduces plasma levels of MCP-1
rom baseline levels when compared with placebo (26).
ombined therapy with simvastatin and losartan or ramipril
ignificantly decreases MCP-1 levels more than mono-
herapy alone in hypercholesterolemic, hypertensive patients
Fig. 3) (27,28). Distinct biological actions of simvastatin
nd losartan or ramipril therapies on lipoproteins and the
ngiotensin system to improve endothelium-dependent vas-
ular function and reduce MCP-1 levels might explain
eneficial effects of combination therapy. Fibrates reduce
igure 3. Percent change in monocyte chemoattractant protein (MCP)-1
evels from respective pretreatment values after treatment with simvastatint
lone, combined therapy, and losartan alone (p  0.030 by analysis of
ariance [ANOVA]) (27). The SEM is identified by bars.RP-induced expression of MCP-1 in human umbilical
ein endothelial cells (29). Rosiglitazone treatment reduces
lasma MCP-1 and CRP in obese patients (30).
RP. Pro-inflammatory cytokines including IL-1beta,
L-6, and tumor necrosis factor (TNF)-alpha are released
rom macrophages within the vessel wall during an inflam-
atory response. These cytokines mediate distant inflam-
atory effects, including activation of hepatic genes (Fig. 4)
ncoding acute phase reactants fibrinogen, CRP, and serum
myloid A. C-reactive protein induces synthesis of cyto-
ines, CAMs, and tissue factor in monocytes and endothe-
ial cells (2,31). Tissue factor activates the extrinsic coagu-
ation cascade, providing a link between inflammation and
hrombosis.
More than 20 prospective epidemiologic studies demon-
trate that high-sensitivity CRP is an independent predictor
f risk of myocardial infarction, stroke, peripheral arterial
isease, and sudden cardiac death, even in apparently
ealthy individuals (32).
Esposito et al. (33) investigated effects of weight loss and
ifestyle changes on vascular inflammatory markers in obese
omen. After two years, body mass index decreased more in
he intervention group than in control subjects, as did serum
oncentrations of IL-6, IL-18, and CRP, whereas adi-
onectin levels increased significantly. Beneficial effects of
Mediterranean-style diet on endothelial function and
ascular inflammatory markers were documented in pa-
igure 4. Pro-inflammatory cytokines such as interleukin (IL)-1beta, IL-6
nd tumor necrosis factor (TNF)- released from injured arteries initiate
epatic synthesis of acute phase reactants. Some acute phase reactants have
ffects on the arterial segment and contribute to the inflammatory response.
odified from Koh KK (2).ients with the metabolic syndrome. Compared with
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December 6, 2005:1978–85 Inflammatory Markers and Metabolic Syndromeatients consuming the control diet, patients consuming a
editerranean-style diet had significantly reduced serum
oncentrations of high-sensitivity CRP, IL-6, IL-7, and
L-18 as well as decreased insulin resistance (34). In
ddition, two recent studies demonstrate that exercise train-
ng with weight reduction lowers CRP levels significantly
35,36). After supervised aerobic exercises, both weight and
RP levels were decreased; however, changes in CRP levels
ere not proportionally associated with the extent of weight
eduction. In quartile analysis of percent weight reduction,
he largest weight reduction quartile did not show signifi-
ant decreases in CRP levels, whereas the middle quartiles
howed remarkable CRP decreases. Considering inflamma-
ory status, there might be an optimal pace of exercise
ombined with weight loss (35). In another study, CRP
evels decreased significantly with training, although none of
he CRP variants were associated with training-induced
RP changes. C-reactive protein219G/A and732A/G
enotypes and haplotypes and exercise training appear to
odulate CRP levels; however, training-induced CRP re-
uctions are independent of genotype at these loci (36).
Simvastatin or atorvastatin lowers CRP in hyperlipidemic
oronary patients (37). After statin therapy, the reduced
rogression of atherosclerosis is significantly related to
reater reductions in CRP levels. Patients with low CRP
evels have better clinical outcomes than those with higher
evels, regardless of LDL cholesterol level (38,39).
C-reactive protein upregulates AT1 receptors in vascular
mooth muscle cells. These effects are attenuated by losartan
40); however, in hypertensive patients, losartan, irbesartan,
r candesartan do not significantly lower serum CRP (41).
nterestingly, simvastatin combined with ramipril signifi-
antly reduces CRP levels more than monotherapy alone in
ypercholesterolemic diabetic patients (Fig. 5) (42). Feno-
brate therapy significantly lowers CRP levels in patients
ith hypertriglyceridemia or combined hyperlipidemia
igure 5. Percent change in high-sensitivity C-reactive protein (hsCRP)
evels from respective pretreatment values after treatment with simvastatinb
lone, combined therapy, and ramipril alone (p  0.004 by analysis of
ariance [ANOVA]) (42). Median values are provided.43,44). Rosiglitazone reduces CRP levels in patients with
ype 2 diabetes (30,45). In addition, CRP attenuates sur-
ival, differentiation, and function of endothelial progenitor
ells, in part, by reducing expression of endothelial NO
ynthase. Rosiglitazone inhibits the negative effects of CRP
n endothelial progenitor cells (46).
NF-alpha. Tumor necrosis factor-alpha is a cytokine
ssociated with coronary atheroma that is secreted from
ndothelial and smooth muscle cells as well as macrophages
nd adipose cells (Fig. 4). It enhances monocyte recruitment
nto developing atherosclerotic lesions and might help link
besity with atherosclerosis. Association of LDL accumu-
ation in rat arteries with TNF-alpha expression suggests a
ole for inflammation in early-stage atherosclerosis (47).
lasma levels of TNF-alpha are persistently elevated among
atients at increased risk for recurrent coronary events (48).
eight loss in response to lifestyle modification in obese
ndividuals is accompanied by decreased TNF-alpha levels
49). Simvastatin and fenofibrate treatment in hyperlipid-
mia significantly lowers plasma levels of TNF-alpha
50,51). Candesartan or rosiglitazone therapy significantly
owers plasma levels of TNF-alpha in hypertensive or obese
iabetic subjects (26,30).
L. Interleukin-6 is the principal procoagulant cytokine. It
ncreases plasma concentrations of fibrinogen, plasminogen
ctivator inhibitor type 1, and CRP (52). Elevated levels of
L-6 are associated with increased risk of future myocardial
nfarction in healthy men (53).
Lifestyle modifications including Mediterranean-style
iet and weight loss reduce serum concentrations of IL-6,
L-7, and IL-18 in obese women (33,34). Simvastatin
ignificantly lowers serum IL-6 levels (54). Exercise, either
lone or in combination with pravastatin, reduces IL-8
evels after 12 weeks in subjects with the metabolic syn-
rome (when compared with pravastatin alone or non-
xercise control group). This suggests a protective role of
xercise to reduce inflammation (24). In human aortic
mooth muscle cells, PPAR-alpha activators inhibit expres-
ion of IL-6. In patients with mild hyperlipidemia, fenofi-
rate therapy decreases circulating levels of IL-6 (55).
osiglitazone does not reduce IL-6 levels in patients with
ype 2 diabetes compared with placebo (45). Interestingly,
osiglitazone and troglitazone significantly potentiate TNF-
lpha–induced production of IL-6 and/or IL-8 in epithelial
ells. Thus, thiazolidinediones might enhance the inflam-
atory response in epithelial cells, a previously unappreci-
ted effect (56).
Interleukin-1 is the prototypical inflammatory cytokine
nd a critical early mediator of inflammation. Patients with
oronary artery disease have markedly elevated levels of IL-1
57). Levels are particularly elevated in unstable disease.
tatin therapy causes marked reduction in IL-1 in periph-
ral blood mononuclear cells. Enalapril and losartan therapy
n patients with stable angina pectoris decreases release of
L-1 and IL-6 (58). In combined hyperlipidemia, fenofi-
rate therapy reduces IL-1beta levels (44).
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Inflammatory Markers and Metabolic Syndrome December 6, 2005:1978–85D40 ligand. The pro-inflammatory mediator CD40 li-
and (CD40L) is expressed on CD4 T cells and activated
latelets. Both membrane-bound and soluble CD40L
sCD40L) interact with CD40L expressed on vascular cells.
D40 ligand plays an important role in a cascade of
nflammatory and proatherothrombotic functions (59).
Patients with unstable angina have higher concentrations
f sCD40L than those with stable angina or healthy
olunteers, perhaps due to release from activated platelets or
lymphocytes (60). Elevated plasma levels of sCD40L
dentify patients with acute coronary syndromes at height-
ned risk of death and recurrent myocardial infarction,
ndependent of other predictive variables (61).
Statin administration reduces elevated plasma levels of
CD40L in patients with hypercholesterolemia (62). Ben-
ficial effects of statin therapy on CD40/CD40L dyad
ight be due to the fact that lowering lipids and lipoprotein
xidation reduces expression of stimulators of CD40 and/or
D40L. In addition, reduction of cytokine-induced CD40/
D40L expression likely requires lipid-independent anti-
nflammatory functions of statins, such as reduced signaling
ia NF-kappaB (63). Candesartan therapy reduces sCD40L,
ndependent of blood pressure lowering effects (64). Fibrate
nd rosiglitazone treatment also reduce sCD40L levels (44,65).
diponectin. Adiponectin is one of a number of proteins
ecreted by adipose cells that might couple regulation of
nsulin sensitivity with energy metabolism and serve to link
besity with insulin resistance. Adiponectin stimulates pro-
uction of NO (66), reduces expression of adhesion mole-
ules in endothelial cells, and decreases cytokine production
rom macrophages by inhibiting NF-kappaB signaling
hrough cyclic adenosine monophosphate (cAMP)-
igure 6. Adiponectin, a cytokine secreted by adipose cells, plays a key role
n opposing insulin resistance. Adiponectin has novel vascular actions to
irectly stimulate production of NO in endothelial cells using phosphati-
ylinositol (PI) 3-kinase-dependent pathways involving phosphorylation of
ndothelial nitric oxide synthase (eNOS) by adenosine-monophosphate–
ctivated protein kinase (AMPK) (66). Others report that adiponectin
educes expression of adhesion molecules in endothelial cells and decreases
ytokine production from macrophage by inhibiting nuclear transcriptionz
actor NF-kappaB signaling through cyclic adenosine monophosphate
cAMP)-dependent pathway (67,68).ependent pathways (Fig. 6) (67,68). Interleukin-6 inhibits
diponectin expression and secretion in 3T3-L1 adipocytes
69). Adiponectin and TNF-alpha reciprocally inhibit pro-
uction of each other in adipose tissue. In particular,
hysiological concentrations of adiponectin inhibit TNF-
lpha–induced monocyte adhesion to human aortic endo-
helial cells as well as expression of various adhesion
olecules (Fig. 6) (67). Thus, adiponectin might indirectly
nhibit CRP and IL-6 expression through its ability to
nhibit production of TNF-alpha.
Plasma levels of adiponectin are negatively correlated
ith adiposity, and decreased plasma adiponectin levels are
bserved in patients with obesity and type II diabetes (70).
ecreased levels of adiponectin might play a key role in the
evelopment of both insulin resistance and atherosclerosis.
Lifestyle modification significantly increases adiponectin
evels in diabetic or obese subjects (33,49). Treatment with
emocapril and candesartan significantly increases adiponec-
in levels as well as insulin sensitivity without affecting
egree of adiposity (71). In hypercholesterolemic, hyperten-
ive patients, losartan alone or combined therapy with
imvastatin and losartan significantly increases plasma adi-
onectin levels relative to baseline measurements, whereas
imvastatin therapy alone does not (Fig. 7) (27). Potential
echanisms for losartan to increase adiponectin levels
nclude direct effects of losartan on insulin-stimulated glu-
ose uptake, promotion of adipogenesis (72), and induction
f PPAR-alpha activity that promotes adipocyte differenti-
tion (73). Recent clinical trials suggest that renin-
ngiotensin system blockade lowers risk of development of
ype II diabetes. One mechanism underlying this effect
ight be an increase in adiponectin levels (27,42).
Fenofibrate therapy significantly increases plasma adi-
onectin levels and insulin sensitivity in patients with
rimary hypertriglyceridemia (43). Administration of thia-
igure 7. Percent change in adiponectin levels from respective pretreat-
ent values after treatment with simvastatin alone, combined therapy, and
osartan alone (p  0.001 by analysis of variance [ANOVA]) (27). The
EM is identified by bars.olidinediones significantly increases plasma adiponectin
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December 6, 2005:1978–85 Inflammatory Markers and Metabolic Syndromeoncentrations in insulin-resistant humans and rodents
ithout affecting body weight. Adiponectin messenger-
NA expression is normalized or increased by thiazo-
idinediones in the adipose tissues of obese mice (74). In
ultured 3T3-L1 adipocytes, thiazolidinediones enhance
xpression and secretion of adiponectin in a dose- and
ime-dependent manner. Rosiglitazone or pioglitazone
herapy significantly increases adiponectin levels in diabetic
ubjects (70,75).
LINICAL IMPLICATIONS
andomized clinical trials demonstrate that statins, fibric
cids, angiotensin-converting enzyme (ACE) inhibitors,
nd angiotensin II type I receptor blockers improve
ndothelium-dependent dilation and reduce vascular in-
ammation resulting in reduced cardiovascular events
Fig. 2). Patients with the metabolic syndrome are increas-
ng in number and comprise one of the largest groups of
ndividuals with obesity, hyperlipidemia, hypertension, and
nsulin resistance. Distinct biological actions of statin and
CE inhibitors or angiotensin II type I receptor blockers
herapies on lipoproteins and the angiotensin system im-
rove endothelium-dependent vascular function by distinct
echanisms (Fig. 2) (76). Indeed, combination therapy has
eneficial additive effects on endothelial function and in-
ammatory markers that might explain positive outcomes of
ecent clinical trials (77–80). This might be due to com-
ined effects of respective monotherapies to improve endo-
helial function and reduce inflammation. Thus, additive
eneficial effects of combined therapy are predicted to
educe cardiovascular events more than monotherapy with
ither drug alone, particularly in patients with the metabolic
yndrome.
In the Prevention of Events with Angiotensin Convert-
ng Enzyme Inhibition (PEACE) trial, addition of tran-
olapril to the regimen of lipid-lowering drugs did not
rovide any further benefit in terms of preventing death
rom cardiovascular events (81). By contrast, perindopril
ignificantly reduced relative risk of this primary end point
y 20% in a patient cohort in which 58% were also receiving
ipid-lowering therapy (80). The Heart Outcomes Preven-
ion Evaluation (HOPE) trial showed that ramipril signif-
cantly reduces the relative risk of major vascular outcomes
y 25% in patients also receiving lipid-lowering drugs (79).
otential explanations for the negative results of the
EACE trial include: an underpowered trial—only 8,290
f a planned 14,100 patients were enrolled; the primary
utcome was changed to include revascularization; and
ailure to reach maximal dose because of adverse effects
82,83). Indeed, a meta-analysis of the HOPE, PEACE,
nd EUROPA data shows significant reductions in mortal-
ty, reinfarction, and stroke (82). Thus, there are clear
enefits of adding ACE inhibitors (particularly high-dose)
n patients with vascular disease without left ventricular
ysfunction.
1UTURE PROSPECTS
nflammation is an important pathogenic factor in athero-
clerosis and coronary heart disease, particularly in the
ontext of diabetes, obesity, and the metabolic syndrome.
iet, exercise, cardiovascular drugs, and insulin sensitizers
mprove endothelium-dependent vascular function and re-
uce inflammation by distinct mechanisms. This might help
xplain beneficial effects of combination therapies in recent
linical trials. Thus, there is a scientific rationale for recom-
ending a combination of lifestyle modifications and mul-
iple drugs from separate classes to prevent atherosclerosis
nd coronary heart disease. Recent evidence suggests that
ross-talk between inflammatory-signaling pathways and
nsulin-signaling pathways causes both metabolic insulin
esistance and endothelial dysfunction that synergize to
redispose to cardiovascular disorders in the metabolic
yndrome (84). Prospective studies are needed to examine
he relationships between reductions in inflammatory bio-
arkers such as CRP, improved insulin sensitivity, and
rimary end points including outcomes of cardiovascular
vents and the incidence of diabetes.
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